Pharmaceutical Subsidiary Exclusion: Which Company Bears the Consequence?

Pharmaceutical subsidiary exclusion can stop federal healthcare programs from paying for a subsidiary’s drugs while the parent continues operating under separate terms. The settlement headline names the business everyone recognizes. The agreement decides which company loses access to government payment, which company takes over the assets, and which managers must change how the drugs are sold. If you work in sales, manufacturing or compliance, that distinction reaches the product and the decisions you see every day.

The Parent’s Name Does Not Tell the Whole Story

A pharmaceutical settlement can put the payment obligation on the parent and other obligations on a named subsidiary. The company that pays, the company operating the plant and the company subject to exclusion need to be identified separately.

Pfizer’s 2009 resolution said Pfizer agreed to pay $1 billion to resolve civil False Claims Act allegations involving promotion of Bextra, Geodon, Zyvox and Lyrica for uses the government programs did not cover, and alleged kickbacks to prescribers. The payment came with an obligation to change how the business operated. Senior executives and board members had to complete annual compliance certifications. The announcement assigned more than $102 million from the federal civil recovery to six whistleblowers whose cases triggered the investigation.

GlaxoSmithKline’s 2010 manufacturing settlement gives the distinction a factory floor. SB Pharmco Puerto Rico was the subsidiary operating the Cidra manufacturing facility. GSK agreed to pay $600 million in the civil settlement over allegations that it caused government programs to pay for substandard drugs. The whistleblower whose case led to that civil settlement was to receive approximately $96 million from its federal share.

The United States alleged that GSK sold batches of Kytril, Bactroban, Paxil CR and Avandamet whose strength, purity or quality fell materially short of what its FDA applications specified. A quality employee’s knowledge of the affected lots connects the manufacturing problem to the products sold and the claims paid. Taxpayers allegedly paid for drugs that fell short of the quality GSK had promised.

Serono’s Companies Had Different Obligations

Serono’s resolution put federal-program exclusion on Serono Laboratories and compliance obligations on Serono Holding. In its October 2005 announcement, the Justice Department said Serono Laboratories would be excluded from all federal health care programs for at least five years.

The civil settlement was $567 million, with approximately $51.8 million collectively for the employee whistleblowers. The government alleged that Serono used unapproved software to diagnose AIDS wasting and generate prescriptions for Serostim, and paid for physician trips. The resolution reached different parts of the business through exclusion, a civil payment and controls covering Serono Holding and other companies.

For an insider, the useful connection is between the sales practice, the resulting prescription and the government payment. The exclusion tells another part of the story: which company can participate afterward.

Can the Parent Continue Federal Program Sales?

A pharmaceutical parent can continue federal program sales under terms that exclude its subsidiary. ISTA Pharmaceuticals shows how specific those terms can be: the agreement addressed the assets, the labels on the drugs, the inventory still held by the companies and the stock already in distribution.

Bausch+Lomb acquired ISTA in June 2012. The May 2013 resolution included a $15 million civil settlement over allegations that ISTA’s marketing of Xibrom caused false claims to government healthcare programs. Xibrom was approved to treat pain and inflammation following cataract surgery. The civil allegations concerned promotion for other uses that the programs did not cover, as well as kickbacks that allegedly produced false claims. The announcement assigned approximately $2.5 million from the federal civil recovery to a whistleblower.

Under the divestiture agreement described by the Justice Department, ISTA agreed to exclusion for 15 years, effective six months after the settlement. It would transfer all assets to Bausch+Lomb or a Bausch+Lomb subsidiary and stop shipping ISTA-labeled drugs within six months of the agreement.

The inventory distinction was unusually concrete. Six months after the divestiture agreement took effect, ISTA-labeled drugs still held by ISTA or Bausch+Lomb would no longer be reimbursable by Medicare, Medicaid or other federal health care programs. ISTA-labeled drugs already in the stream of commerce would remain reimbursable. The label alone did not decide the result. Where the stock sat at the cutoff mattered too.

The HHS Office of Inspector General explained why it accepted that arrangement. Bausch+Lomb had no corporate relationship with ISTA during the improper conduct, bought it more than a year after that conduct ended, and did not hire its executives or senior management.

The Parent’s Sales Operation Had Obligations Too

Bausch+Lomb also agreed to maintain a compliance and ethics program that reached the way prescription products were promoted. Commercial personnel were excluded from final decisions on educational grants. Sales agents were to discuss approved uses and send requests about unapproved uses to medical affairs. The program prohibited payments intended to induce prescriptions reimbursed by federal healthcare programs.

The executive responsible for global pharmaceuticals had to review the program annually and certify its effectiveness. The subsidiary’s exclusion therefore came with obligations inside the continuing parent business. For someone who knows who actually approved an educational grant or directed a sales campaign, those obligations make the decision chain especially important.

An Exclusion Date Belongs to a Particular Company

Endo illustrates why the exact company name needs to accompany the exclusion date. The HHS Office of Inspector General’s exclusion list recorded April 20, 2025 as the exclusion date for Endo Health Solutions. The Justice Department’s February 2024 resolution named that same company.

The distinction reaches people as well as companies. The Inspector General’s exclusion entry for Nostrum Laboratories’ chief executive recorded exclusion on June 30, 2025 for breach of a settlement agreement. The entry concerned the executive. It did not name the company as excluded.

Exclusion Can Be Avoided or Kept in Reserve

An agreement can preserve access to federal health care programs while requiring changes inside the business. Exclusion can also remain available if those obligations go unmet.

In explaining the Avanir Pharmaceuticals resolution and the Heritage Pharmaceuticals resolution, the Justice Department cited the consequences that exclusion would have for American consumers and the importance of preserving the businesses’ financial viability. Continued access to medicine was part of the government’s enforcement decision.

Insys Therapeutics offers a more specific example of an exclusion power kept in reserve. Under its 2019 resolution the Inspector General kept the power to exclude Insys until it did what its compliance agreement required.

This distinction matters to a compliance employee reading a settlement announcement. The agreement may identify continuing obligations, a promised release after performance, or an exclusion with an effective date. Those terms answer different questions about what the company must do next.

Why the Business Can Outlast the Settlement

A settlement can cost hundreds of millions while leaving the parent in business. Taxpayers paid the claims, and a large settlement does not by itself show that the practices inside the company changed.

Public Citizen’s 2018 report, reviewing pharmaceutical settlements from 1991 through 2017, described the historical parent-company pattern plainly:

The report also described corporate integrity agreements as a way for companies to undertake reforms and annual reporting in exchange for the Inspector General’s agreement not to exclude them. It observed that Pfizer and GlaxoSmithKline had repeat settlements while still under earlier agreements. That is where someone inside the continuing business may know more than the public announcement tells us.

FDA approval and government reimbursement answer different questions: whether a drug may be sold, and whether a program will pay for it. ISTA’s inventory cutoff shows how that payment question can turn on where the stock sits.

What the Insider Can Connect

The useful evidence connects the operating company, the decisions inside it and the government money. In the GSK manufacturing allegations, that connection ran through affected batches and the quality represented to government purchasers. In the ISTA settlement, it ran through promotion, prescribing and program claims. The parent compliance terms added another connection: who approved the activity and who certified that the controls worked.

A manufacturing employee may know which lots failed the promised specifications. Someone in sales may know who directed the promotion. A compliance employee may know what reached the annual review. We connect that knowledge to the company obligations and payment records that make a pharmaceutical whistleblower case specific.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Who Made the Decision

If the settlement names a subsidiary but you know who directed the sales, controlled the plant or signed the compliance review, talk to our whistleblower experts. We work beside you to connect those decisions to government payments and build your pharmaceutical whistleblower case. We stay with you through the process and bring in pharmaceutical fraud whistleblower lawyers who understand corporate structures.